Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00867529 · OUTCOME

Overall Survival and Progression-free Survival

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma · Source last updated 2018-01-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
At 6 months and then every year thereafter, up to 18 months

What was measured

Number of patients surviving and number of patients surviving without progressive/relapsed disease, post-transplant.

Groups in this outcome

Treatment (Rituximab Pre- and Post-transplant)

Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity. rituximab: Given IV peripheral blood stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation nonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Rituximab Pre- and Post-transplant)63

Reported measurements

PFS - 6 Months
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Rituximab Pre- and Post-transplant)48Not reportedNot reportedNot reportedNot reported
PFS - 1 Year
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Rituximab Pre- and Post-transplant)39Not reportedNot reportedNot reportedNot reported
PFS - 1.5 Years
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Rituximab Pre- and Post-transplant)34Not reportedNot reportedNot reportedNot reported
OS - 6 Months
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Rituximab Pre- and Post-transplant)52Not reportedNot reportedNot reportedNot reported
OS - 1 Year
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Rituximab Pre- and Post-transplant)44Not reportedNot reportedNot reportedNot reported
OS - 1.5 Years
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Rituximab Pre- and Post-transplant)36Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        48
    title
    PFS - 6 Months
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        39
    title
    PFS - 1 Year
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        34
    title
    PFS - 1.5 Years
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        52
    title
    OS - 6 Months
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        44
    title
    OS - 1 Year
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        36
    title
    OS - 1.5 Years
denoms
  1. counts
    1. group Id
      OG000
      value
      63
    units
    Participants
description
Number of patients surviving and number of patients surviving without progressive/relapsed disease, post-transplant.
groups
  1. description
    Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity. rituximab: Given IV peripheral blood stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation nonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies
    id
    OG000
    title
    Treatment (Rituximab Pre- and Post-transplant)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
At 6 months and then every year thereafter, up to 18 months
title
Overall Survival and Progression-free Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice